Liverpool and Macarthur Cancer Therapy Centres, Sydney, New South Wales, Australia.
University of New South Wales, Sydney, New South Wales, Australia.
J Med Imaging Radiat Oncol. 2021 Jul;65(4):454-459. doi: 10.1111/1754-9485.13254. Epub 2021 Jun 4.
Mongolia has a population of 3.3 million and is classified by the WHO as a lower middle-income country. Cancer is now a major public health issue and one of the leading causes of mortality. Within the framework of an existing national cancer control plan, the National Cancer Centre of Mongolia (NCCM) aimed to implement 3D conformal radiation planning and linac-based treatment delivery.
In 2018, an opportunity arose for collaboration between the Mongolia Society for Radiation Oncology (MOSTRO), the National Cancer Centre Mongolia (NCCM), the Asia-Pacific Radiation Oncology Special Interest Group (APROSIG) of the Royal Australian and New Zealand College of Radiologists (RANZCR) and the Asia-Pacific Special Interest Group (APSIG) of the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) and radiation therapists (RTTs) from a range of Australian centres. We describe here the results to date of this collaboration.
Despite a number of significant technical and practical barriers, successful linac commissioning was achieved in 2019. Key factors for success included a leadership receptive to change management, stable bureaucracy and health systems, as well as a synchronised effort, regional cooperation and mentorship.
Future directions for ongoing collaborative efforts include a continued focus on education, practical training in radiotherapy planning and delivery and postgraduate education initiatives. Radiotherapy safety and quality assurance remain an ongoing priority, particularly as technological advances are sequentially implemented.
蒙古人口为 330 万,被世界卫生组织列为中低收入国家。癌症现已成为主要的公共卫生问题之一,也是导致死亡的主要原因之一。在国家癌症控制计划的框架内,蒙古国家癌症中心(NCCM)旨在实施 3D 适形放射治疗计划和直线加速器治疗。
2018 年,蒙古放射肿瘤学会(MOSTRO)、蒙古国家癌症中心(NCCM)、澳大利亚和新西兰皇家放射医师学院亚太辐射肿瘤学特别兴趣小组(APROSIG)和澳大利亚医学物理科学家和工程师亚太特别兴趣小组(APSIG)与来自澳大利亚多家中心的放射治疗师(RTTs)之间展开了合作机会。我们在此描述了此次合作的最新成果。
尽管存在许多重大的技术和实际障碍,但直线加速器于 2019 年成功投入使用。成功的关键因素包括乐于接受变革管理的领导层、稳定的官僚机构和卫生系统,以及协调一致的努力、区域合作和指导。
正在进行的合作努力的未来方向包括继续关注教育、放射治疗计划和交付的实践培训以及研究生教育计划。放射治疗安全和质量保证仍然是一个持续的优先事项,特别是随着技术的逐步实施。